Q-omics provides the consensus-scored RANBP10 profile across patient tissues and cancer cell-line models. RANBP10 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, RANBP10 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, RANBP10 protein abundance shows 20,689 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LUSC, THCA, and GBM as cancer lineages where RANBP10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RANBP10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RANBP10 survival associations across molecular data types. RANBP10 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RANBP10 RNA expression–survival associations across cancer types. High RANBP10 expression shows unfavorable associations in LUSC, LUAD and LGG, but favorable associations in SCLC, UCEC and UCS. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUSC as the clearest survival context for RANBP10 RNA expression.
This table summarizes RANBP10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 9. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RANBP10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RANBP10 shows lower tumor expression in THCA, LUAD and BRCA and higher tumor expression in KIRP, COAD and KIRC. The THCA box plot shows higher RANBP10 RNA expression in normal versus tumor tissue (log2 FC = −1.420, t-test p < 0.001).
This table shows molecular features associated with RANBP10 in patient tissues and cancer cell lines. In patient samples, RANBP10 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, RANBP10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
